AM ResearchBioprintingMedical Research

Servier and Poietis partner on 4D bioprinting of liver tissues

Partnership seeks to improve detection of drug-induced liver lesions

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, are partnering to use Poietis’s 4D bioprinting technology for the development and production of liver tissues.

This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. Such lesions are rare but can have serious consequences for patients. This hepatotoxic potential is poorly detected by current preclinical models. Beyond animal models, various models based on human cell cultures are available, but most lack longevity and complexity, which limits their usefulness in toxicology. Poietis’s 4D bioprinting technology has emerged as an innovative technology capable of helping to overcome these limitations.

“We are thrilled to announce the launch of this partnership with Servier. Their non-clinical safety team is highly experienced when it comes to using the full range of in vitro toxicology tools, and it is very gratifying to have been selected as a partner in their search for new cellular models and new techniques. The developments we are planning will strive for greater precision, and the associated application requirements, in which control over morphogenesis and standardization issues, are essential,” said Bruno Brisson, General Manager and Chief Business Officer at Poietis.

The partnership is based on the reproduction of a new, complex, bioprinted human liver tissue containing lines of human liver cells and immunocompetent cells within a defined architecture designed to imitate human liver tissue in vitro.

According to Hélène Aerts, in charge of Biologie Servier’s in vitro platform, Poietis’ technology’s ability to include different cell types within a single extracellular matrix will make it possible to recreate a microtissue in which inflammatory response and tissue remodeling phenomena can be studied in vitro, “This project will advance our understanding of hepatotoxicity mechanisms and allow us to offer tests to detect, as early as possible, any adverse effects when developing our medicinal products,” said Nancy Claude, Director of Non-Clinical Safety at Servier. “We can expect to see fewer undesirable hepatic effects in patients as early as the clinical test phase.”

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, the company employs 21.700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for research and development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.

Dr. Fabien Guillemot, CEO and Chief Scientific Officer at Poietis is convinced that the long-term partnership with Servier to develop liver tissue with bioprinting technology is an important step in the deployment of 4D bioprinting in the pharmaceutical industry. Following our collaboration with KUL on cartilage bioprinting for the purposes of tissue repair, this new scientific partnership with Laboratoires Servier is in line with the strategy of Poietis, which aims to extend the use of its technology beyond its initial applications in dermocosmetics,” he added.


Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...

Davide Sher

Since 2002, Davide has built up extensive experience as a technology journalist, market analyst and consultant for the additive manufacturing industry. Born in Milan, Italy, he spent 12 years in the United States, where he completed his studies at SUNY USB. As a journalist covering the tech and videogame industry for over 10 years, he began covering the AM industry in 2013, first as an international journalist and subsequently as a market analyst, focusing on the additive manufacturing industry and relative vertical markets. In 2016 he co-founded London-based VoxelMatters. Today the company publishes the leading news and insights websites and, as well as VoxelMatters Directory, the largest global directory of companies in the additive manufacturing industry.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.